BriaCell Therapeutics Corp.
TSX:BCT.TOBiotechnology
Healthcare
$5.75 +18.88%
+$0.94 today
- Market cap
- $50.02M
- Beta
- 1.53
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$4.23
52W Low $3.68High $20.40
Volume 0.00M
Average 0.01M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$28.51M
FY 2025 · Annual
Investing Cash Flow
-$7.74M
FY 2025 · Annual
Financing Cash Flow
$46.00M
FY 2025 · Annual
+941.1% YoYCash Flow Statement
USD
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Net Income | (13.82M) | (26.84M) | (20.3M) | (4.93M) | (26.63M) |
| Depreciation & Amortization | 15.26K | 15.27K | 15.27K | 83.9K | 107.93K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.97M | 3.07M | 2.19M | 1.8M | 0 |
| Change in Working Capital | (2.28M) | (391.29K) | (3.53M) | 7.05M | (1.93M) |
| Accounts Receivables | 9.94K | (11.53K) | 5.23K | (732.58K) | 742.6K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.41M) | 249.16K | 660.46K | 6.05M | (3.93M) |
| Other Working Capital | (886.38K) | (628.93K) | (4.2M) | 1.74M | 1.26M |
| Other Non-Cash Items | 6.36M | 11.66M | (2.12M) | (28.14M) | (58.73K) |
| Operating Cash Flow | (7.75M) | (12.48M) | (23.74M) | (24.13M) | (28.51M) |
| Capital Expenditures | 0 | 0 | 0 | (456.8K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (225K) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (7.74M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (681.8K) | (7.74M) |
| Debt Repayment | (330.4K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 51.62M | 0 | 4M | 4.42M | 46M |
| Common Stock Repurchased | 0 | (10.17M) | (47.29K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.71M | 6.43M | 1.59K | 0 | 0 |
| Financing Cash Flow | 65M | (3.74M) | 3.95M | 4.42M | 46M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (84.08K) |
| Net Change in Cash | 57.25M | (16.23M) | (19.79M) | (20.39M) | 9.67M |
| Free Cash Flow | (7.75M) | (12.48M) | (23.74M) | (24.58M) | (28.51M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$26.6M
+ D&A$107.9K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$1.9M
- Other Non-Cash-$58.7K
= Operating Cash Flow-$28.5M
- Capex$0
= Free Cash Flow-$28.5M
Analysis
FY2025 free cash flow is -$28.5M. FCF conversion is 107.1% of net income. Operating cash flow was -$28.5M, with capex of $0. The largest bridge item is Working Capital at -$1.9M.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
No filings found.
Does BCT.TO generate free cash flow?
BriaCell Therapeutics Corp. (BCT.TO) generated -$28.51M of free cash flow in fiscal 2025.
How much operating cash flow does BCT.TO produce?
Operating cash flow was -$28.51M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.